Login Register Cart 0
Generic placeholder image

当代肿瘤药物靶点

Editor-in-Chief

ISSN (Print): 1568-0096
ISSN (Online): 1873-5576

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe Translate in English
Clinical Trial

Selinexor (KPT-330)，一种口服选择性核出口抑制剂(SINE)化合物，联合FOLFOX用于转移性结直肠癌(mCRC)患者——I期临床试验的最终结果

卷 20, 期 10, 2020

页: [811 - 817] 页: 7

弟呕挨: 10.2174/1568009620666200628105727

open access plus

摘要

背景：Selinexor是一种口服核出口化合物选择性抑制剂，特异性阻断染色体区域维持蛋白1。 目的：评价逐步加大剂量selinexor联合5-氟尿嘧啶、亚叶酸钙和奥沙利铂(mFOLFOX6)治疗转移性结直肠癌(mCRC)患者的安全性和耐受性。 方法：在这项多中心I期试验中，符合以奥沙利铂为基础的治疗方案的mCRC患者，被纳入每两周的第1、3、8天接受一次口服selinexor 联用mFOLFOX6治疗。主要终点为最大耐受剂量。次要终点为毒性、总有效率、无进展生存期和总生存期。 结果：共有10名患者入选，他们之前接受过奥沙利铂(6/10)、伊立替康(8/10)、贝伐珠单抗(6/10)或抗EGFR治疗(5/10)。连续4名患者接受40 mg selinexor联用mFOLFOX6治疗剂量。所有四名患者都经历了剂量限制毒性，并在中位两个周期后退出研究。因此，这个剂量水平被认为是有毒的，没有进一步的患者评估在这个剂量。6名患者以20mg selinexor联用mFOLFOX6治疗剂量入组。尽管耐受性较好，4名患者在第一个周期后退出(患者意愿)，只有2名患者继续到疾病进展。最常见报道的治疗不良事件为恶心(80%)、腹泻(70%)、呕吐(60%)、疲劳(60%)、厌食(40%)和视力受损(40%)。由于治疗暴露时间较短，未观察到相关临床活动。 结论：在转移性结直肠癌患者中，selinexor联用mFOLFOX6是不可耐受的。可以评估其他给药方案或组合。临床试验标识NCT02384850。

关键词: 转移性结直肠癌，结直肠癌，mCRC

« Previous
图形摘要

[1]
Siegel, R.; Ward, E.; Brawley, O.; Jemal, A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J. Clin., 2011, 61(4), 212-236.
[http://dx.doi.org/10.3322/caac.20121 ] [PMID: 21685461]
[2]
Bokemeyer, C.; Bondarenko, I.; Hartmann, J.T.; de Braud, F.; Schuch, G.; Zubel, A.; Celik, I.; Schlichting, M.; Koralewski, P. Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study. Ann. Oncol., 2011, 22(7), 1535-1546.
[http://dx.doi.org/10.1093/annonc/mdq632 ] [PMID: 21228335]
[3]
Douillard, J.Y.; Siena, S.; Cassidy, J.; Tabernero, J.; Burkes, R.; Barugel, M.; Humblet, Y.; Bodoky, G.; Cunningham, D.; Jassem, J.; Rivera, F.; Kocákova, I.; Ruff, P.; Błasińska-Morawiec, M.; Šmakal, M.; Canon, J.L.; Rother, M.; Oliner, K.S.; Wolf, M.; Gansert, J. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J. Clin. Oncol., 2010, 28(31), 4697-4705.
[http://dx.doi.org/10.1200/JCO.2009.27.4860 ] [PMID: 20921465]
[4]
Grapsa, D.; Syrigos, K.; Saif, M.W. Bevacizumab in combination with fluoropyrimidine-irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy for first-line and maintenance treatment of metastatic colorectal cancer. Expert Rev. Anticancer Ther., 2015, 15(11), 1267-1281.
[http://dx.doi.org/10.1586/14737140.2015.1102063 ] [PMID: 26506906]
[5]
El-Tanani, M.; Dakir, H.; Raynor, B.; Morgan, R. Mechanisms of nuclear export in cancer and resistance to chemotherapy. Cancers (Basel), 2016, 8(3)E35
[http://dx.doi.org/10.3390/cancers8030035 ] [PMID: 26985906]
[6]
Gravina, G.L.; Senapedis, W.; McCauley, D.; Baloglu, E. Shacham.; Festuccia, C. Nucleo-cytoplasmic transport as a therapeutic target of cancer. J. Hematol. Oncol., 2014, 7, 85.
[http://dx.doi.org/10.1186/s13045-014-0085-1 ] [PMID: 25476752]
[7]
Turner, J.G.; Dawson, J.; Sullivan, D.M. Nuclear export of proteins and drug resistance in cancer. Biochem. Pharmacol., 2012, 83(8), 1021-1032.
[http://dx.doi.org/10.1016/j.bcp.2011.12.016 ] [PMID: 22209898]
[8]
Niu, M.; Chong, Y.; Han, Y.; Liu, X. Novel reversible selective inhibitor of nuclear export shows that CRM1 is a target in colorectal cancer cells. Cancer Biol. Ther., 2015, 16(7), 1110-1118.
[http://dx.doi.org/10.1080/15384047.2015.1047569 ] [PMID: 25996664]
[9]
Abdul Razak, A.R.; Mau-Soerensen, M.; Gabrail, N.Y.; Gerecitano, J.F.; Shields, A.F.; Unger, T.J.; Saint-Martin, J.R.; Carlson, R.; Landesman, Y.; McCauley, D.; Rashal, T.; Lassen, U.; Kim, R.; Stayner, L.A.; Mirza, M.R.; Kauffman, M.; Shacham, S.; Mahipal, A. First-in-class, first-in-human phase i study of selinexor, a selective inhibitor of nuclear export, in patients with advanced solid tumors. J. Clin. Oncol., 2016, 34(34), 4142-4150.
[http://dx.doi.org/10.1200/JCO.2015.65.3949 ] [PMID: 26926685]
[10]
Turner, J.G.; Dawson, J.; Cubitt, C.L.; Baz, R.; Sullivan, D.M. Inhibition of CRM1-dependent nuclear export sensitizes malignant cells to cytotoxic and targeted agents. Semin. Cancer Biol., 2014, 27, 62-73.
[http://dx.doi.org/10.1016/j.semcancer.2014.03.001 ] [PMID: 24631834]
[11]
Bahlis, N.J.; Sutherland, H.; White, D.; Sebag, M.; Lentzsch, S.; Kotb, R.; Venner, C.P.; Gasparetto, C.; Del Col, A.; Neri, P.; Reece, D.; Kauffman, M.; Shacham, S.; Unger, T.J.; Jeha, J.; Saint-Martin, J.R.; Shah, J.; Chen, C. Selinexor plus low-dose bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma. Blood, 2018, 132(24), 2546-2554.
[http://dx.doi.org/10.1182/blood-2018-06-858852 ] [PMID: 30352784]
[12]
Chari, A.; Vogl, D.T.; Gavriatopoulou, M.; Nooka, A.K.; Yee, A.J.; Huff, C.A.; Moreau, P.; Dingli, D.; Cole, C.; Lonial, S.; Dimopoulos, M.; Stewart, A.K.; Richter, J.; Vij, R.; Tuchman, S.; Raab, M.S.; Weisel, K.C.; Delforge, M.; Cornell, R.F.; Kaminetzky, D.; Hoffman, J.E.; Costa, L.J.; Parker, T.L.; Levy, M.; Schreder, M.; Meuleman, N.; Frenzel, L.; Mohty, M.; Choquet, S.; Schiller, G.; Comenzo, R.L.; Engelhardt, M.; Illmer, T.; Vlummens, P.; Doyen, C.; Facon, T.; Karlin, L.; Perrot, A.; Podar, K.; Kauffman, M.G.; Shacham, S.; Li, L.; Tang, S.; Picklesimer, C.; Saint-Martin, J.R.; Crochiere, M.; Chang, H.; Parekh, S.; Landesman, Y.; Shah, J.; Richardson, P.G.; Jagannath, S. Oral Selinexor-dexamethasone for triple-class refractory multiple myeloma. N. Engl. J. Med., 2019, 381(8), 727-738.
[http://dx.doi.org/10.1056/NEJMoa1903455 ] [PMID: 31433920]
[13]
Kuruvilla, J.; Savona, M.; Baz, R.; Mau-Sorensen, P.M.; Gabrail, N.; Garzon, R.; Stone, R.; Wang, M.; Savoie, L.; Martin, P.; Flinn, I.; Jacoby, M.; Unger, T.J.; Saint-Martin, J.R.; Rashal, T.; Friedlander, S.; Carlson, R.; Kauffman, M.; Shacham, S.; Gutierrez, M. Selective inhibition of nuclear export with selinexor in patients with non-Hodgkin lymphoma. Blood, 2017, 129(24), 3175-3183.
[http://dx.doi.org/10.1182/blood-2016-11-750174 ] [PMID: 28468797]
[14]
Gounder, M.M.; Zer, A.; Tap, W.D.; Salah, S.; Dickson, M.A.; Gupta, A.A.; Keohan, M.L.; Loong, H.H.; D’Angelo, S.P.; Baker, S.; Condy, M.; Nyquist-Schultz, K.; Tanner, L.; Erinjeri, J.P.; Jasmine, F.H.; Friedlander, S.; Carlson, R.; Unger, T.J.; Saint-Martin, J.R.; Rashal, T.; Ellis, J.; Kauffman, M.; Shacham, S.; Schwartz, G.K.; Abdul Razak, A.R. Phase IB study of selinexor, a first-in-class inhibitor of nuclear export, in patients with advanced refractory bone or soft tissue sarcoma. J. Clin. Oncol., 2016, 34(26), 3166-3174.
[http://dx.doi.org/10.1200/JCO.2016.67.6346 ] [PMID: 27458288]
[15]
Services H: Common terminology criteria for adverse events (CTCAE) version 4.03. 2010; National Institutes of Health, National Cancer Institute: USA, 2016.
[16]
Eisenhauer, E.A.; Therasse, P.; Bogaerts, J.; Schwartz, L.H.; Sargent, D.; Ford, R.; Dancey, J.; Arbuck, S.; Gwyther, S.; Mooney, M.; Rubinstein, L.; Shankar, L.; Dodd, L.; Kaplan, R.; Lacombe, D.; Verweij, J. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer, 2009, 45(2), 228-247.
[http://dx.doi.org/10.1016/j.ejca.2008.10.026 ] [PMID: 19097774]
[17]
Hesketh, P.J.; Kris, M.G.; Grunberg, S.M.; Beck, T.; Hainsworth, J.D.; Harker, G.; Aapro, M.S.; Gandara, D.; Lindley, C.M. Proposal for classifying the acute emetogenicity of cancer chemotherapy. J. Clin. Oncol., 1997, 15(1), 103-109.
[http://dx.doi.org/10.1200/JCO.1997.15.1.103 ] [PMID: 8996130]
[18]
Cassidy, J.; Clarke, S.; Díaz-Rubio, E.; Scheithauer, W.; Figer, A.; Wong, R.; Koski, S.; Rittweger, K.; Gilberg, F.; Saltz, L. XELOX vs. FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results. Br. J. Cancer, 2011, 105(1), 58-64.
[http://dx.doi.org/10.1038/bjc.2011.201 ] [PMID: 21673685]
[19]
Díaz-Rubio, E.; Tabernero, J.; Gómez-España, A.; Massutí, B.; Sastre, J.; Chaves, M.; Abad, A.; Carrato, A.; Queralt, B.; Reina, J.J.; Maurel, J.; González-Flores, E.; Aparicio, J.; Rivera, F.; Losa, F.; Aranda, E. Spanish Cooperative Group for the Treatment of Digestive Tumors Trial. Phase III study of capecitabine plus oxaliplatin compared with continuous-infusion fluorouracil plus oxaliplatin as first-line therapy in metastatic colorectal cancer: final report of the Spanish cooperative group for the treatment of digestive tumors trial. J. Clin. Oncol., 2007, 25(27), 4224-4230.
[http://dx.doi.org/10.1200/JCO.2006.09.8467 ] [PMID: 17548839]

Rights & Permissions Print Cite
Article Metrics
44
3
© 2024 Bentham Science Publishers | Privacy Policy